TOP TEN perturbations for 1552991_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552991_at
Selected probe(set): 1552991_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552991_at (1552991_at) across 6672 perturbations tested by GENEVESTIGATOR:

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.4535437
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):-1.373662
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):1.2508059
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

sarcoidosis study 6 (lacrimal gland tissue) / normal lacrimal gland tissue

Relative Expression (log2-ratio):-1.2311764
Number of Samples:12 / 7
Experimental sarcoidosis study 6 (lacrimal gland tissue)
Lacrimal gland tissue samples obtained from patients who suffered from sarcoidosis. Biopsies were formalin-fixed and paraffin-embedded.
Control normal lacrimal gland tissue
Normal lacrimal gland tissue samples. The control tissue was obtained during surgery on eyes with non-inflamed orbits, such as blepharoplasties and enucleations. Biopsies were formalin-fixed and paraffin-embedded.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.2156057
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%) / ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)

Relative Expression (log2-ratio):-1.1891918
Number of Samples:5 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 2d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control ingenol mebutate study 1 (uninvolved skin; 2d; 0.05%)
Punch biopsies of uninvolved skin obtained from actinic keratosis patients after 2 days treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the second topical application with ingenol mebutate from cca 25-cm2 area of uninvolved, normal-appearing, aged but non-sun-exposed skin on the inner aspect of the upper arm. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:

actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%) / actinic keratosis study 4 (lesion; baseline)

Relative Expression (log2-ratio):-1.184763
Number of Samples:6 / 6
Experimental actinic keratosis study 4 (lesion; ingenol mebutate; 1d; 0.05%)
Punch biopsies of skin lesions obtained from actinic keratosis patients after 1 day treatment with ingenol mebutate 0.05% gel. Samples were taken one day after the first topical application with ingenol mebutate from cca 25 cm2 treated area. The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had 2-5 clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm. ATC code:
Control actinic keratosis study 4 (lesion; baseline)
Punch biopsies of skin lesions obtained from actinic keratosis (AK) patients before treatment (baseline). The biopsies were formalin fixed and paraffin embedded. Patients were ≥ 18 years of age and had two to five clinically typical, visible, and discrete AK lesions within a contiguous 25 cm2 area on the upper extremity (dorsum of hands or forearm) and with one additional AK lesion located 1 to 5 cm from the AK treatment area. Further the donors had uninvolved skin area on the inner aspect of the upper arm.

thyroid eye disease study 1 (lacrimal gland tissue) / normal lacrimal gland tissue

Relative Expression (log2-ratio):-1.1036348
Number of Samples:7 / 7
Experimental thyroid eye disease study 1 (lacrimal gland tissue)
Lacrimal gland tissue samples obtained from patients who suffered from thyroid eye disease (TED). Biopsies were formalin-fixed and paraffin-embedded.
Control normal lacrimal gland tissue
Normal lacrimal gland tissue samples. The control tissue was obtained during surgery on eyes with non-inflamed orbits, such as blepharoplasties and enucleations. Biopsies were formalin-fixed and paraffin-embedded.

glioma study 5 / non-tumor brain tissue

Relative Expression (log2-ratio):0.9373064
Number of Samples:12 / 9
Experimental glioma study 5
Primary tumor tissue sample from the supratentorial brain of pediatric patients with glioblastoma multiformae.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

Xq12–q13.3 duplication syndrome study 1 / normal lymphoblastoid cell line sample

Relative Expression (log2-ratio):0.91739845
Number of Samples:2 / 13
Experimental Xq12–q13.3 duplication syndrome study 1
Lymphoblastoid cell line samples from two brothers with Xq12–q13.3 duplication. The patients are affected by severe autism and global developmental delay with multiorgan involvement.
Control normal lymphoblastoid cell line sample
Lymphoblastoid cell line samples from healthy subjects.